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August 7, 2008
Dear Reader,
Over the past 10 years IDCR has strived to bring you the most up-to-date, relevant information on
managing infectious diseases in the correctional setting. As we celebrate a decade of publication, we
would like to personally thank you for your continued support and engagement. Unfortunately, this
will be IDCR’s last issue as an independent publication. While it is our every intention to continue
publishing issues under a new umbrella organization, these plans have yet to be determined. Please
read the letter from the editor to learn more.
Important Things to Know:
Continuing medical education credit will continue to be available through August 2009.
Please refer to the instructions and expiration date of the issue when applying for credit.
All of our issues (February 1999-July/August 2008) will be available online at
www.IDCROnline.org through 2014. Click on the Archives link at the top of the web page for
a complete list of archived issues.
We have made these arrangements to allow maximum access to IDCR content during this time of
uncertainty. We apologize for any confusion or inconvenience these changes may cause. If you have
any questions feel free to contact me at (401)453-2068 or idcrme@gmail.com.
Sincerely,
Elizabeth Closson
Managing Editor
ABOUT IDCR
IDCR, a forum for correctional
problem solving, targets correctional
physicians, nurses, administrators,
outreach workers, and case man-
agers. Published monthly and dis-
tributed by fax and email, IDCR is
ACCME accredited and free of
charge. Since its founding in 1998,
IDCR has served as an important
resource for correctional health care
providers by offering the newest
and most relevant information on
the management and treatment of
infectious diseases within the
correctional setting.
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provided by Nova Southeastern University
Health Professions Division. This publication
is jointly sponsored by IDCR and NSU. This
activity has been planned and implemented
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DISCLOSURES AND CREDENTIALS:
RAPID HIV TESTING: COMING TO A JAIL NEAR YOU?
OBJECTIVES
The learner will be able to explain the different types of FDA-
approved rapid HIV tests, how they are used, and details
related to their sensitivity and specificity.
The learner will be able to discuss how to communicate rapid
HIV test results and how to incorporate HIV counseling with the
rapid testing process.
The learner will be able to describe recent studies related to
feasibility and cost analysis of rapid testing in jails.
The purpose of this monograph is to
increase the knowledge of correc-
tional health care providers on FDA-
approved rapid HIV tests, communi-
cating results offering HIV counsel-
ing for rapid testing, and on the ben-
efits of implementing a rapid HIV
testing program in a jail setting.
Purpose Statement
If you have any problems with this newsletter please call (401)453-2068 • fax (401)272-7562 or e-mail us at idcrme@gmail.com
Instructions for Credit
To obtain credit read the Main Article,
Spotlight, and HIV 101 sections. When
completed with these items, complete
the post test and evaluation on the last
page of the monograph. You must
receive a test score of at least 75% and
respond to all evaluation questions to
receive a certificate. Mail or fax the
post test and evaluation to:
IDCR
146 Clifford Street
Providence, RI 02903
or fax it to (401)272-7562
Go to www.AAHIVM.org to learn about
membership, continuing education and
the new partnership with IDCR
101: HIV 101 FDA-Approved Rapid HIV Antibody
Screening Tests
Spotlight: An Overview of Microbicides
Through Her Own Eyes
Sue Coe and Eric Avery | 2007 | Woodcut
www.DocArt.com
Main Article: Rapid HIV Testing: Coming to a jail
near you?
Brooke E. Hoots, MSPH
The University of North Carolina
School of Public Health
David A. Wohl, MD
Associate Professor of Medicine
University of North Carolina
AIDS Clinical Research Unit
Introduction
An estimated 1.2 million people in the
United States are living with HIV/AIDS,1 and
an estimated 25% of these people are
unaware of their HIV infection.2 In response,
the Centers for Disease Control and
Prevention (CDC) in September 2006
issued their Revised Recommendations for
HIV Testing of Adults, Adolescents, and
Pregnant Women in Health-Care Settings,
aiming to reduce barriers to HIV testing and
increase the number of Americans who
know their HIV status.3 A centerpiece of
these recommendations is a move to opt-
out HIV screening for all patients ages 13-64
years in all health care settings, including
correctional health care facilities. The basis
for this recommendation is that by increas-
ing the availability of HIV testing the number
of people who know their result will also
increase and, as demonstrated, will subse-
quently reduce behaviors likely to transmit
HIV, and will help reduce the spread of the
virus. 4,5
Although detection of HIV infection is a cor-
nerstone of HIV prevention, testing alone is
insufficient. According to the CDC, almost
one-third of individuals in 2000 who tested
and found to be HIV-infected did not return
to receive their test result.6 The turn-around
time for conventional HIV testing has often
been an insurmountable obstacle to HIV
screening of at-risk populations such as
those who are homeless or migratory. A
failure to return for HIV test results is not
unique to community HIV screening; the
transient nature of those who are jailed has
prevented wider spread HIV testing in this
setting. A study of the HIV testing experi-
ences of jail inmates conducted in Rhode
Island found that 50% of those who had pre-
viously been tested for the virus had not
received the result of the test even though a
majority of prior HIV screening had been
performed in correctional settings.7
Since becoming available in the United
States in 2002, rapid HIV tests have allowed
for the expansion of HIV screening in both
medical and non-medical settings, including
prisons and jails.8 Rapid HIV tests yield
results in less than 30 minutes and substan-
tially increase the number of people who
receive their test result by eliminating the
need for a return visit, and are becoming
increasingly utilized in non-clinical settings
such as community-based screening
events.9 Rapid HIV testing is particularly
suited to use in jails due to the transient
nature of inmates in this environment.
Testing can be conducted quickly, does not
require extensive training of the tester, and
the results are provided immediately.
Another Rhode Island study found that
among 95 jail inmates, 79% of whom had
not received an HIV test result during a prior
incarceration, 100% were informed of the
results of their rapid HIV test during their
current jail stay.10
FDA-approved rapid tests
Since February 2002, six rapid tests have
been approved by the Food and Drug
Administration (FDA) (See HIV 101).11 Four
of these tests (OraQuick ADVANCE Rapid
HIV-1/2 Antibody Test, Clearview HIV-1/2
STAT-PAK, Clearview COMPLETE HIV 1/2,
and Uni-Gold Recombigen HIV Test) are
approved for use with whole blood speci-
mens obtained by finger stick or venipunc-
ture. OraQuick ADVANCE may also be
used with oral fluid samples. These tests
have received waivers under the Clinical
Laboratory Improvement Amendments
(CLIA) that set quality standards for all test-
ing on human specimens, enabling these
tests to be used in settings that do not
include laboratories when they utilize whole
blood specimens or oral fluid.12, 13 Settings
using CLIA-waived tests only need to enroll
in CLIA, pay a fee, and follow the test man-
ufacturer's instructions for use.
The two tests that only use serum or plasma
samples (MultiSpot HIV-1/HIV-2 Rapid Test
and Reveal G3 Rapid HIV-1 Antibody Test)
are classified as "moderately complex"
under CLIA and are not waived, meaning
they are subject to specific laboratory and
personnel requirements. Similarly, when
the four tests with waivers for use with oral
fluid and/or whole blood specimens are
used with plasma or serum samples (only
plasma in the case of OraQuick ADVANCE),
they are no longer CLIA-waived.
All of the FDA-approved rapid tests are
interpreted visually. The test strip or mem-
brane is covered with HIV antigens that bind
HIV antibodies that may be present in the
patient specimen. The test kits also contain
colorimetric reagents that generally bind to a
control region on the test strip and to HIV
antibodies to create an indicator that is visu-
ally detectable.14
With the exception of the MultiSpot HIV-
1/HIV-2 Rapid Test, which takes about 10-
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Dear Correctional Colleagues,
The air is velvet with humidity. The grass is lush and green. Daylight stretches away
into the evening and warm breezes embrace us. We delight in the glory of summer,
but know the time is limited, and one day soon, we'll feel the first crisp hint of fall. With
fall will come a change, and as it goes with summer, so it goes with IDCR.
This will be IDCR's last issue as an independent non-profit (501c3) organization. We
can look back in pride at our work - ten years of solid work almost to the day - first as
HIV Education Prison Project (HEPP) and more recently as IDCR. We've written, edit-
ed and published more than 100 issues in our nine volumes of work over the past
decade, on topics ranging from HIV testing and treatment of inmates to the manage-
ment of chickenpox outbreaks in correctional institutions. We pushed the envelope.
We took action. We advocated for better HIV care.
We can positively claim that our years of productive work have improved the care of
inmates with HIV and the management of infectious diseases in prisons. We believe
that we collectively contributed to improving the standards of health care in our spe-
cialized setting, just as we were able to build strong relationships across state (and
institutional) lines and national borders. We celebrate our teamwork and look back on
our work with pride and amazement, but these glorious, halcyon days, are coming to
a close.
Dear reader, just as summer must end one day soon, we will publish this last issue of
IDCR and move on to the next thing. IDCR will be reborn in a new form, under a dif-
ferent guise, as yet to be determined. We, the founders, editors, the IDCR editorial
board, and the advisors of IDCR, appreciate your involvement as readers and hope
that you enjoy the end of our glorious summer. We wish for you the best that the turn-
ing seasons may bring.
Annie De Groot, MD
Executive Editor
LETTER FROM THE EDITOR
15 minutes to conduct, all of the rapid tests
take less than 5 minutes to set up and
perform.12 The window periods for reading
the results as measured from the last step of
the testing process are listed in Table 1. If
the tests are not read within these window
periods, they are considered invalid. It is
therefore important to make sure that per-
sonnel coordinate patient intake and pro-
cessing to fit within these window periods.
Sensitivity and specificity
All of the FDA-approved rapid tests have
sensitivities and specificities that are com-
parable to conventional blood-based HIV
enzyme immunoassays (EIAs) antibody
tests.15 Sensitivity is the probability that the
test result will be positive given that the per-
son is truly HIV-infected, while specificity is
the probability that the test result will be
negative given that the person is truly HIV-
uninfected. While the sensitivity and speci-
ficity of a test are constant properties, the
predictive value, or the usefulness of the
test in classifying people with infection,
varies depending on the prevalence of dis-
ease in the population being tested.16 The
negative predictive value of a rapid HIV test,
or the probability that a person is HIV-unin-
fected given that his or her test is negative,
is high at the HIV prevalence observed in
most testing sites in the US.17 However, the
positive predictive value of a rapid test, or
the probability that a person is HIV-infected
given that his or her test is reactive, is lower
in populations with low HIV prevalence (For
more information on why this is true,
visit: http://www.cdc.gov/hiv/topics/testing
/rapid/index.html. Therefore, in correction-
al settings where the prevalence of HIV
infection is generally higher than the gener-
al population, the positive predictive value of
rapid HIV testing will likely exceed that of
most community settings. Reactive rapid
tests results, like conventional EIAs, are
considered preliminary and require confir-
matory testing to rule out false-positive
results.16 Confirmatory testing is usually
done with a Western blot or indirect
immunoflourescence assay.15
Recently, several clusters of higher than
expected numbers of false-positive results
have been noted in settings using rapid HIV
tests of oral fluid.18 As reported in the
Morbidity and Mortality Weekly Report
(MMWR), the causes of these clusters have
not been elucidated, but investigations are
under way to determine what factors might
be associated with this unexplained variabil-
ity. Several programs using oral fluid-based
testing have changed their procedures and
now repeat the rapid test on whole-blood
specimens from patients who have reactive
oral fluid tests. This strategy allows the pro-
grams to take advantage of the conve-
nience of oral fluid rapid testing while
decreasing the number of preliminary false-
positives. Regardless of the test used, it is
important to remember that confirmatory
testing is required to confirm all reactive
rapid HIV tests.
Communicating the meaning of the rapid
test result
Because the negative predictive value of a
rapid HIV test is high, a person who
receives a negative HIV rapid test result can
be told that he or she is not HIV-infected.14
However, if a person has had a possible
recent exposure to HIV (within 3 months),
he or she could be in the acute phase of HIV
infection and have not yet developed
detectable HIV antibodies. Such persons
should be counseled regarding the possibil-
ity of acute HIV infection and be retested
within 3 months. If symptoms or high suspi-
cion for acute HIV infection are present,
testing for HIV RNA may be warranted.
Individuals with reactive rapid test results
should be counseled on risk-reduction
behaviors while awaiting the results of con-
firmatory testing. The CDC recommend
conveying to the patient that the preliminary
test is positive and that the individual should
take precautions to avoid transmitting the
virus to others while awaiting confirmatory
testing.19 If the confirmatory test result is
negative or indeterminate, the individual
should be retested after one month to rule
out test error and the possibility of early HIV
infection that may not yet be detectable by
Western blot.20 An indeterminate test may
be an indication of early HIV infection and
testing for acute HIV with an HIV RNA test
may be necessary. Consultation with an HIV
expert should be sought in such cases.
HIV counseling with rapid testing
The FDA requires that individuals who
undergo rapid testing receive an information
sheet provided by each manufacturer with
its rapid HIV test kits.14 This sheet includes
general information on HIV and AIDS as
well as specifics about the test and what the
results mean and don’t mean. Clients
should also receive prevention counseling.
With conventional HIV testing, there are two
visit opportunities for prevention counseling
for clients who return for their results. With
rapid testing, there may be either one or two
opportunities for counseling depending on
whether or not confirmatory testing is
required and the patient returns for these
test results.19 Point-of-care testing requires
that personnel have the ability and the pri-
vacy to provide positive test results on the
spot. If an individual with a reactive rapid
test does not return for confirmatory testing
results, he or she should at least leave the
initial visit knowing that there is a high prob-
ability of infection.14
Rapid HIV testing in jails
While rapid HIV testing has been incorpo-
rated into the HIV screening procedures of
jails across the United States, there are few
published reports describing their applica-
tion in this setting. Results of a CDC-sup-
ported effort to introduce rapid HIV testing
for screening of jail inmates in Florida,
Louisiana, New York, and Wisconsin pro-
vide some of the best data on this
approach.8 Between 2003 and 2006,
33,211 inmates, 6% of all those booked,
were voluntarily HIV tested with a rapid test
between. More than 99% of these inmates
received their HIV test results; 1.3% had a
reactive test result and 97% of those who
underwent confirmatory testing were found
to be HIV-infected. For two-thirds of those
found to be HIV-infected, the diagnosis was
new. In these settings, rapid HIV testing was
found to be feasible and did lead to the iden-
tification of over 250 individuals who were
unaware of their HIV infection.
An analysis of the costs associated with this
CDC demonstration project, including the
cost of identifying previously undiagnosed
HIV infection, has also been published.21
This analysis focused on data collected
from 2004 to 2005. Although the costs were
extremely variable by site, the study found
that the average cost of HIV testing for
those without infection was between $29.46
and $44.98. The cost of testing was signifi-
cantly higher for HIV-infected inmates and
was estimated between $71.37 and
$137.72 per inmate. The discrepancy in
costs relative to HIV serostatus is due to the
extra post-test counseling required for indi-
viduals who test positive for HIV. Most of the
cost of rapid HIV testing was due to variable
costs, including time for counseling and
testing, nondurable goods and supplies,
and test kits. Overall, the average cost per
newly diagnosed HIV infection ranged from
a low of $2,451 to high of $25,288. The
high end of the spectrum of the cost per new
HIV diagnosis is a function of greater travel
and other expenses at one site coupled with
a low overall HIV prevalence in that state.
Conclusions
Rapid testing should be used to encourage
behavior change to limit the spread of HIV
infection and to link those who test positive
into a system of care. Such testing reduces
significant barriers to individuals learning
their HIV status, allows for HIV testing
opportunities in settings without committed
laboratories, and facilitates patients receiv-
ing their test results at the testing visit. HIV
screening of jailed inmates with rapid HIV
tests is attractive given the quick turn
around time for results and the accuracy of
these tests. However, such testing is not
without costs, including the expense of the
tests themselves, the training of staff to per-
form the testing, and counseling and confir-
matory testing, when necessary. The cost
per new HIV diagnosis drops with increas-
ing prevalence of HIV infection. Therefore,
jails in areas with a higher prevalence of HIV
infection may find rapid HIV testing to be
more affordable than those where HIV infec-
tion is less common. In all settings, the ben-
efits of the detection of undiagnosed HIV
infection, including prevention of opportunis-
tic conditions and secondary transmission
of the virus, may well justify any added
expense.
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Why are microbicides needed?
Over the last 15 years, there has been an
increasing feminization of the HIV epidemic
with the proportion of women infected dramati-
cally rising. Women are at greater risk for HIV
infection due to physiologic and socioeconom-
ic reasons. The Centers for Disease Control
and Prevention (CDC) estimate that 25% of
new HIV infections in the United States (US)
occur in women. In the US in 2004, HIV was
the leading cause of death in black women
aged 25-34 years and the 5th and 6th leading
cause of death in all women aged 35-44 and
25-34, respectively. In parts of the world with
more generalized epidemics, such as sub-
Saharan Africa, women account for almost
60% of those living with HIV. These worrisome
statistics point to a clear need for HIV preven-
tion technologies aimed at protecting women
from acquisition of HIV. The current prevention
methods, condoms and male circumcision,
pertain to men and must be initiated by males.
Although a female condom is available, the
cost is prohibitive and there may be poor
acceptance from the woman’s partner. Female
initiated methods of prevention are an impor-
tant part of a comprehensive HIV prevention
plan, and methods that women can use to pro-
tect themselves from HIV infection are
urgently needed.
What are microbicides?
Microbicides are primarily vaginal products that
are being developed to prevent the acquisition
of HIV infection. To date, no effective microbi-
cide exists, and work is ongoing to develop the
concept of an intravaginal method of protection
into an effective microbicide product.
Microbicides are being developed in a variety
of topical forms including gels, films, soft gel
capsules and intravaginal rings. The mecha-
nisms of action of microbicide candidates dif-
fer; early generation products are non specific
and directed at multiple organisms that cause
sexually transmitted infections (STIs) including
HIV, and later generation candidates contain
antiretroviral agents and are directed specifi-
cally at disabling HIV. Developed in the 1990s,
the first generation microbicides were expect-
ed to reduce the acquisition of HIV infection by
killing or immobilizing pathogens and by boost-
ing the vagina’s natural defenses. These
agents displayed in vitro activity against HIV
and other sexually-transmitted pathogens,
including HSV-2. The first generation products
were coitally dependent, meaning that they
needed to be applied just before intercourse.
The newest candidate microbicides contain
antiretroviral agents and are expected to pre-
vent infection through blocking replication of
HIV. These products are designed to be used
independent of sex with dosing once daily for
gel forms or once monthly in the case of micro-
bicides formulated as intravaginal rings.
Research to Date
Researchers have been working to develop
microbicide products for over a decade; these
efforts have resulted in Phase III clinical stud-
ies to test whether candidate products protect
against HIV infection. To date, 6 candidate
microbicide gels have or are being tested in 8
large scale trials. None of the candidates thus
far have shown efficacy in these studies. The
first trial tested the spermicide nonoxynol-9 (N-
9) and results from this study were published in
2000. Unfortunately, in this study, harm was
found and there were more infections in the
women who used N-9 compared to those who
used placebo gel.
More recently, results from trials testing 3 other
first generation products have been
announced. Two trials testing cellulose sulfate
were halted due to futility and potential harm
(in one trial there was a trend toward more HIV
infections in the women who received product
compared to those who received placebo).
Two trials testing the surfactant agent Savvy®
were stopped for futility, and results from the
single trial testing the product, Carraguard®,
showed that while it was safe, it did not protect
against HIV infection. The results from these
large Phase III trials were considered to be sig-
nificant setbacks to the microbicide field; it is
hoped that the next generation antiretroviral
containing microbicides being developed will
be effective. Results from trials testing the
remaining first generation products,
BufferGel® and PRO2000 are expected in the
next 1-2 years.
The second generation candidates are those
containing compounds with antiretroviral activ-
ity. It is believed that since these products con-
tain drugs with activity directed specifically
against HIV, they will be more potent than the
first generation products. The first generation
products rely on contact with HIV to induce
viral inactivation, and are inserted at the time of
sex, a feature that is believed to decrease
adherence to product. In contrast, since sec-
ond generation products inhibit viral replication
and rely on intracellular concentration of an
antiretroviral agent, they can be used daily and
do not need to be used at the time of sex, a
feature that may improve adherence to prod-
uct. These second generation products are
being formulated as either daily gels or as
intravaginal rings that will be inserted once per
month. A gel made with the currently approved
non nucleotide reverse transcription inhibitor
tenofovir (Viread®) is currently being tested in
a large trial in South Africa. Other drugs being
developed as microbicides but are not yet in
large trials include dapivarine (TMC 120) and
UC-781, both of which are non nucleoside
reverse transcriptase inhibitors. Unlike the non
specific agents, there is the potential for anti-
retroviral containing agents to select for HIV
resistance in the viruses in women who
become infected while using them. Because
this is a recognized concern, there will be care-
ful monitoring for this in the efficacy trials.
To date, research has focused mainly on vagi-
nal microbicides; however it is widely acknowl-
edged that any product that is approved for
vaginal use will be used rectally. Since the
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5vagina and rectum are different environments,
more research needs to be conducted on rec-
tal microbicides. First, it is important to know
about the safety of vaginal products if they are
used rectally, and initial research to answer
safety questions is being conducted.
Determining efficacy of products to prevent
acquisition of HIV through anal sex will also be
an important part of microbicides research.
Lessons learned
The microbicide field has and will continue to
be faced with multiple challenges. Many of the
efficacy trials require thousands of participants
in areas of documented high incidence and as
a result have been conducted in sub-Saharan
Africa. Early stage studies examining safety
and acceptability have been conducted in mul-
tiple areas including North America, Europe,
India and Africa. In the context of these clinical
trials, it is important to educate communities
about the importance of prevention research
and build local awareness and political support
to prevent trial delays and closures.
Microbicide development to date has provided
important lessons to be applied to future work.
These include best ways to perform preclinical
evaluation of products, the need to choose
best-in-class for large scale trials, and concen-
tration on ways to bolster and objectively mea-
sure adherence. High levels of adherence to
product are essential to measuring effective-
ness in the context of trials. Other challenges
to microbicide development include manufac-
turing and delivery. Products must be accept-
able, affordable and accessible to those who
need them most. In the context of the correc-
tional setting, access to proven microbicides
may be limited in the same manner that access
is limited to condoms and clean needles, how-
ever even in this case, correctional facilities
could serve as settings for education about
microbicides as part of interventions to prevent
HIV.
Drug development is a long and costly
process. Microbicide research is no exception
and will take time. It is important to learn from
past experiences and trials and to thoughtfully
engage in future research.
Path Forward
With an estimated 33.2 million people infected
worldwide and over 2.5 million people becom-
ing infected in 2007, HIV prevention options
are urgently needed. Microbicides will be an
important part of any HIV prevention package
particularly for women who are increasingly at
risk. A safe and effective microbicide will
enable women to take control of protecting
themselves from HIV infection.
Centers for Disease Control and Prevention. HIV/AIDS among Women. Accessed 3 July 2008. http://www.cdc.gov/hiv/topics/women/resources/factsheets/women.htm.
UNAIDS. 2006 Report on the Global AIDS Epidemic. May 2006.
International Partnership for Microbicides. About Microbicides. Accessed 7 July 2008. http://www.ipm-microbicides.org/about_microbicides/english/index.htm.
Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a
randomised controlled trial. The Lancet 2002; 360 (9338): 971-977.
GAO Report-Efforts to Research and Inform the Public about Nonoxynol-9 and HIV. March 2005.
Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, et al. SAVVY Vaginal Gel (C31G) for Prevention of HIV Infection: A Randomized Controlled Trial in Nigeria. PLoS ONE
2008; 3(1): e1474.
Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, et al. SAVVY (C31G) Gel for Prevention of HIV infection in Women: A Phase 3, Double-Blind, Randomized,
Placebo-Controlled Trial in Ghana. PLoS ONE 2007; 2 (12): e1312.
Baleta, Adele. Disappointment at failure of microbicide candidate. Lancet Infectious Disease 2008; 8 (4): 221.
WHO. 2007 Epidemic Update, WHO & UNAIDS. November 2007.
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RESOURCES
SPOTLIGHT: AN OVERVIEW OF...
(continued from page 4)
In resource blessed nations, antiretroviral treatment has been enormously successful in both preventing maternal to fetal transmission of HIV and in
extending the lives of those who are HIV infected. In spite of these successes, it has become increasingly clear that on a global basis we cannot treat
ourselves out of the HIV epidemic. The costs associated with drug procurement and delivery puts treatment beyond the reach of many of those who
are in need. Furthermore, HIV has demonstrated an impressive ability to successfully evolve in response to each newly developed antiretroviral agent.
A brief glance backwards in history provides numerous examples of common infectious diseases that have been either eradicated or rendered uncom-
mon due to advances in prevention, not treatment. In the early part of the 20th century, it would have been difficult to find a family that had not lost
at least one member due to typhoid, diphtheria, smallpox, polio, pertussis, or measles. These and many other once common scourges have been
controlled by improved sanitation and/or effective immunization efforts.
Thus far, efforts to develop an effective HIV immunization have been unsuccessful. Although efforts continue in this area and must eventually suc-
ceed, there is an urgent need for other prevention strategies to augment the use of barrier methods. In spite of decades of experience demonstrat-
ing that condoms are highly effective in preventing transmission of HIV and other sexually transmitted infections, most of those who are incarcerat-
ed have been denied access to these cheap and effective life-protecting devices. There are some notable glimmers of hope in this arena, including
a pilot project that is slated to begin within the California Department of Corrections and Rehabilitation. Similarly, it is unlikely that the incarcerated
will be on the forefront of access to immunization and microbicidal approaches to HIV prevention. That notwithstanding, correctional health care
providers must keep up on developments in this important field. Only by doing so will we be able to effectively advocate for our patients when sci-
ence catches up with the promise. Human sexuality and physical expressions thereof do not end simply because one is confined behind bars. To
pretend otherwise and to deny access to proven prevention measures for HIV or any other fatal illness is in this writer's point of view indefensible and
nothing short of deliberate indifference.
JB
Editors Note
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6The paradoxical effects of using antiretroviral-based microbi-
cides to control HIV epidemics: risk for HIV drug resistance
This study examines the potential effects of microbicide use in pre-
venting HIV infection and transmission. Researchers used a 10 year
epidemiological model simulation to predict the effects of an anti-
retroviral-based microbicide public health intervention. Microbicides
are being developed as a tool to prevent infections in women and to
empower women. Paradoxically, the researchers found that the ARV-
based microbicides may benefit men more than women and that this
effect will be exacerbated if high-risk microbicides are used.
The same number of infections will be prevented whether the micro-
bicide is high-risk or low-risk. However, low risk microbicides will gen-
erate fewer resistant cases, even if adherence is high. If resistance
does emerge as a result of ARV-based microbicides, the resulting
strains will only be resistant to the specific class of drugs in the prod-
uct. Therefore, therapeutic options, including other classes of ARVs,
for the individuals who acquire resistance will be reduced but not
eliminated. Prevalence of resistance would be greatest in women
(22% median; IQR 8-50%), but transmitted resistance would be 12
times greater in men (2.6% median; IQR 0.8-7%) than women. The
researchers recommend monthly monitoring for seroconversion.
However, they also found that although the monthly tests decrease
the risk to participants during the trial, the use of microbicides
increases resistance in the general population when frequent testing
does not occur.
Wilson DP, Coplan PM, Wainberg MA, et al. The paradoxical effects
of using antiretroviral-based microbicides to control HIV epidemics.
Proc Natl Acad Sci U S A 2008;105(28):9835-40. Epub 2008 Jul 7.
Alcohol abuse and dependence has big impact on cirrhosis in
HIV/HCV coinfection
Researchers discovered that alcohol abuse and dependence signifi-
cantly increases the risk of advanced fibrosis/cirrhosis among those
with HIV, HCV and HCV/HIV coinfection. However, this effect was
not observed in lesser degrees of alcohol consumptions, which were
defined by NIAAA criteria. The study, Veterans Aging Cohort Study
(VACS), was a longitudinal study of 6,090 age/sex matched
HIV+/HIV- U.S. Veterans at 8 sites. Of the 4,678 veterans with com-
plete data, 425 (9.1%) had advanced fibrosis/cirrhosis. This number
includes 12.5% of the HIV+ and 4.4% of HIV- subjects. Researchers
discovered a trend towards increased liver injury with hazardous or
binge-drinking. However, they only observed a statistically significant
increase in advanced fibrosis/cirrhosis in those with an IDC-9 diag-
nosis of alcohol abuse and dependence (AAD). Among these were
9.5% of the HIV infected, 15.6% of the HCV infected and 33.1% of the
HCV/HIV co-infected. In multivariate analysis, after controlling for
HCV and HIV, alcohol was the strongest correlate of advanced fibro-
sis/cirrhosis. Other significant correlates include age > 50 years,
black race and HBV. Of the subjects with advanced fibrosis/cirrhosis,
38.7% had a diagnosis of ADD. Thus, the conclusion of the study is
that alcohol abuse and dependence is particularly common among
individuals with advanced fibrosis/cirrhosis.
Lim JK, Fultz SL, Goulet JL, et al. Impact of Alcohol Abuse and
Dependence On Liver Fibrosis in a Prospective Cohort of 6090
HIV+/Hiv- U.S. Veterans. Digestive Disease Week. San Diego, CA
May 17-22, 2008
Role of week 4-rapid virological response (RVR) in prediction of
sustained virological response to Peg-IFN plus ribavirin in
HCV/HIV co-infected individuals
This study was performed as a retrospective review of two prospec-
tive, open-label single center studies in HCV/HIV co-infected patients
who attended a specialty outpatient clinic in Dublin, Ireland. The
objective of the study was to evaluate the role of rapid virological
response (RVR) in predicting sustained virological response (SVR)
rates to hepatitis C virus (HCV) therapy. Virological response was
assessed at four intervals: week 4 (RVR), week 12 (EVR – early viro-
logical response), week 24 (EOTR – end of treatment) and 24 weeks
post-completion of treatment (SVR).
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HIV 101: FDA-Approved Rapid HIV Antibody Screening Tests
Clearview HIV 1/2 STAT-PAK
Clearview COMPLETE HIV 1/2
OraQuick ADVANCE Rapid HIV-1/2
Antibody Test§
Uni-Gold Recombigen HIV Test
MultiSpot HIV-1/HIV-2 Rapid Test
Reveal G3 Rapid HIV-1
Antibody Test
Inverness Medical
Professional Diagnostics
(www.invernessmedicalpd.com)
Inverness Medical
Professional Diagnostics
(www.invernessmedicalpd.com)
OraSure Technologies, Inc.
(www.orasure.com)
Trinity Biotech
(www.unigoldhiv.com)
BioRad Laboratories
(www.biorad.com)
MedMira, Inc.
(www.medmira.com)
ManufacturerAssay by Specimen Type*
Whole Blood (finger stick or venipuncture)
Serum or Plasma
* When tests may use other specimen types, it is listed as a table footnote.
† As measured from last step of testing process
_ Can also be used with a serum or plasma sample
§ Can also be used with an oral fluid specimen or plasma sample
Data adapted from References 11 and 12 of the Main Article.
99.7%
(98.9-100)
99.7%
(98.9-100)
99.6%
(98.5-99.9)
100%
(99.5-100)
100%
(99.9-100)
99.8%
(99.0-100)
99.9%
(99.6-100)
99.9%
(99.6-100)
100%
(99.7-100)
99.7%
(99.0-100)
99.9%
(99.8-100)
98.6%
(98.4-98.8)
Sensitivity
(95% CI)
Specificity
(95% CI)
Window Period for
Result Validity†
15-20 minutes
15-20 minutes
20-40 minutes
10-12 minutes
Immediately to
up to 24 hrs
Must be read
immediately
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7XVII International AIDS
Conference (AIDS 2008)
Centro Banamex Convention and
Business Centre
Mexico City, Mexico
August 3-8, 2008
Visit: http://www.aids2008.org/
Improving Health Outcomes for
HIV-Positive Individuals
Transitioning From Correctional
Settings to the Community
Hawthorne, NY-August 12, 2008
Rochester, NY-September 11, 2008
Syracuse, NY-September 15, 2008
Johnson City, NY-October 29, 2008
Amityville, NY-November 10, 2008
Buffalo, NY-November 25, 2008
Contact:
For more information or to register,
email: hivet@health.state.ny.us
Visit: http://www.health.state.ny.us/
diseases/aids/training/addition.htm#
health_outcomes
American Correctional
Association- 138th Congress of
Correction
New Orleans, Louisiana
August 8-13, 2008
Visit: http://www.aca.org/
conferences/Summer08/home.asp
TB Program Managers' Workshop
Newark, NJ
September 9-11, 2008
Visit: www.umdnj.edu/globaltb/
coures/brochures/2008progmanwork
shop.htm
2008 United States Conference on
AIDS (USCA)
Miami, FL
September 18-21, 2008
Visit: www.nmac.org/index
/2008-usca
National Conference on
Correctional Health Care
Chicago, IL
October 18-22, 2008
Visit: http://www.ncchc.org/
education/national2008.html
MRSA & HIV
Live Satellite Videoconference &
Webcast
Wednesday, October 22, 2008
12:30 - 2:30 p.m. (Eastern Time)
Visit: http://www.amc.edu
/hivconference
(518) 262-4674
ybarraj@mail.amc.edu
The 48th Annual ICAAC/IDSA
46th Annual Meeting
Washington, DC
October 25-28, 2008
Visit: www.icaacidsa2008.org/
SAVE THE
DATES
The researchers discovered that the achievement of RVR, a negative HCV-PCR, at week 4 of treatment
is indeed predictive of SVR in this cohort of patients. The positive predictive value of RVR at week 4 for
subsequent SVR in HIV-HCV co-infected patients was 100%, while the negative predictive value was
57%. Sixty percent of the 65 patients achieved SVR (25% genotype 1 / 4, 77% genotype 2 / 3). The sig-
nificant variables associated with SVR were lower median pre-treatment HCV viral load, genotype 2 / 3
disease and achievement of RVR. The researchers suggest that with this evidence, it would be possi-
ble to identify, based on their HCV-PCR test at week four, which of the patients would only need 6 months
of a full dose to achieve SVR. In addition, these findings further strengthen the groups previously pub-
lished recommendation to individualize the duration of HCV therapy for HIV/HCV co-infected patients.
Shea D O, Tuite H, Farrell G, et al. Role of week 4-rapid virological response (RVR) in prediction of sus-
tained virological response to Peg-IFN plus ribavirin in HCV/HIV co-infected individuals. Journal of Viral
Hepatitis 2008;15(7):482-89.
Randomized comparison of 12 or 24 weeks of peginterferon a-2a and ribavirin in chronic hepati-
tis C virus genotype 2 / 3 infection
Researchers discovered that the effectiveness of 12 weeks of combined peginterferon a-2a and ribavirin
treatment is inferior to 24 weeks in patients infected with genotype 2 or 3. The study followed 382 geno-
type 2 / 3 infected patients at 31 centers in Denmark, Finland, Norway, and Sweden who were random-
ly selected for 12 or 24 week therapy. The sustained viral response (SVR) rates, 59% (12 week) and 78%
(24 week), were significantly greater for those who were treated longer, regardless of fibrosis stage and
genotype. In addition, 12-week patients experienced a higher relapse rate (33% versus 12%) than 24-
week patients.
Post hoc analysis identified two groups of patients who responded favorably to short-term treatment;
patients younger than 40 years who have achieved RVR and those 40 years or older with very rapid viro-
logical response, meaning HCV-RNA below 1000 IU/mL on day 7 in addition to achieving RVR. Age was
determined to be a significant factor on the efficacy of treatment. Patients younger than 40 years of age
had decidedly better outcomes than those 40 and over. Thus, if patients with favorable viral kinetic
response to therapy were selected for 12 weeks of therapy, and the demographics were similar to those
in the study, 40% of the total population would be suitable for short-term therapy, which would lead to a
20% reduction in pharmaceutical costs as well as a substantial reduction in side effects along with mini-
mal change of SVR rates.
Findings from this study differ from previous reports on treatment shorter than 24 weeks for patients with
these genotypes. Possible explanations of this difference include a greater proportion of unfavorable
prognostic features included in this study population, differences in ribavirin dosage, and differences in
treatment duration.
Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterfer-
on a-2a and ribavirin in chronic hepatitis C virus genotype 2 / 3 infection. Journal of Hepatology. June
2008.
Khorrami, Pollard & Abir Files Class Action Civil Rights Lawsuit in Federal Court Against
California Prisons for Failure to Properly Treat Inmates With Hepatitis C
The law firm of Khorrami, Pollard & Abir filed a class action law suit in Los Angeles on July 8 contending
that the California Department of Corrections and Rehabilitation (CDCR) is unjustly excluding thousands
of inmate from liver biopsies and hepatitis C anti-retroviral treatment, allowing them to progress to more
advances stages of liver damage. The suit sites the fact that the standard of care as set by the Centers
for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) requires that
patients with Stage II Hepatitis be offered treatment. Contrary to this standard, the CDCR requires
inmates to develop a more advances stage of hepatitis C before they are willing to initiate treatment.
Without Stage II treatment the likelihood of developing cirrhosis, liver failure, and liver cancer dramati-
cally increases. The case was filed on behalf of Kevin Johnson, the lead plaintiff and a current inmate at
California State Prison at Solano. It names the defendant as Robin Dezember, the director of the division
of health services responsible for the health care policies for the CDCR.
"Despite an established standard of care, the California Department of Corrections and Rehabilitation
has adopted protocols designed to exclude patients from diagnostic biopsies and treatment. This is in
contrast to the care and treatment provided to the general population," says Khorrami. "This practice not
only denies inmates proper care and allows their health to deteriorate, but also presents a health danger
of further spreading the disease not only within the prison population but also in the general population
once the infected inmates are released from prison."
Marketwire-July 8, 2008. Accessed 22 July 2008. Available at: http://www.marketwire.com/press-
release/Khorrami-Pollard-and-Abir-Llp-876713.html
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SELF-ASSESSMENT TEST FOR CONTINUING MEDICAL EDUCATION CREDIT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing
Medical Education through the joint sponsorship of Nova Southeastern University Health Professions Division, Inc. (NSU) and IDCR. NSU is accred-
ited by the ACCME to provide continuing medical education for physicians.
NSU designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. The target audience for this educational program
is physicians. Physicians should only claim credit commensurate with the extent of their participation in the activity. Statements of credit will be
mailed within 6 to 8 weeks following the program.
8
In order to receive credit, participants must score at least a 75% on the post test and submit it along with the credit
application and evaluation form to the address/fax number indicated. Statements of credit will be mailed within 4-6 weeks
following the program.
Please print clearly as illegible applications will result in a delay.
Name: _________________________________________________ Profession: __________________________________
License #: ___________________________________ State of License: __________________________________________
Address: ____________________________________________________________________________________________
City: ________________________ State: ________ Zip: ________________________ Telephone: ___________________
Please check which credit you are requesting ___ ACCME or ___ Non Physicians
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
I certify that I participated in the IDCR monograph August 2008 Issue
Please fill in the number of actual hours that you attended this activity.
Date of participation: ______________________
Number of Hours (max. 1): ___________________
Signature: _________________________________________________
Please Submit Completed Application to:
Infectious Disease in Corrections Report
146 Clifford Street, Providence, RI 02903
or fax it to (401)272-7562
Instructions:
• Applications for credit will be accepted until
September 7, 2009.
• Late applications will not be accepted.
• Please anticipate 4-6 weeks to recieve your certificate.
Objectives:
The learner will be able to explain the different types of FDA-approved rapid HIV tests, how they are used, and details related to their sensitivity
and specificity.
The learner will be able to discuss how to communicate rapid HIV test results and how to incorporate HIV counseling with the rapid testing process.
The learner will be able to describe recent studies related to feasibility and cost analysis of rapid testing in jails.
1. Which of the following is NOT an FDA-approved rapid HIV test for use with whole blood
specimens or oral fluid specimens that has received a waiver under the Clinical
Laboratory Improvement Amendments (CLIA) allowing use in settings that do not have
access to a laboratory?
A. OraQuick ADVANCE Rapid HIV-1/2 Antibody Test
B. Clearview HIV 1/2 STAT-PAK
C. MultiSpot HIV-1/HIV-2 Rapid Test
D. Uni-Gold Recombigen HIV Test
2. With the exception of the MultiSpot HIV-1/HIV-2 Rapid Test all FDA-approved rapid
HIV tests take how much time to set up and perform?
A. Between 5 and 20 minutes
B. Less than 10 minutes
C. Between 10-15 minutes
D. Less than 5 minutes
3. As a strategy for decreasing the number of preliminary false-positives using oral
fluid-based testing, many programs have changed their procedures and now repeat the
rapid test on whole-blood specimens from patients who have reactive oral fluid tests.
True or False?
4. An indeterminate HIV test result may be an indication of early HIV infection, and
therefore testing for acute infection with an HIV RNA test may be necessary.
True or False?
5. According to the Spotlight article “An Overview of Microbicides” which of the following is
NOT a characteristic of a second generation microbicide?
A. They contain compounds with antiretroviral activity
B. These products are being formulated as coitally dependent gels or
intravaginal rings
C. There is the potential for antiretroviral containing agents to select for HIV
resistance in the viruses in women who become infected while using them
D. None of the above
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